BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Santer, D. M., Li, D., & Ghosheh, Y. (2022). Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. Nature Communications, 13(1), 6992. Added by: Dr. Enrique Feoli (21/11/2022, 11:55) Last edited by: Dr. Enrique Feoli (21/11/2022, 11:56) |
 |
| Resource type: Journal Article DOI: 10.1038/s41467-022-34709-4 ID no. (ISBN etc.): 2041-1723 BibTeX citation key: Santer2022 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Constitutive innate immunity Creators: Ghosheh, Li, Santer Collection: Nature Communications |
Views: 4/178
|
| Abstract |
|
Interferons induced early after SARS-CoV-2 infection are crucial for shaping immunity and preventing severe COVID-19. We previously demonstrated that injection of pegylated interferon-lambda accelerated viral clearance in COVID-19 patients (NCT04354259). To determine if the viral decline is mediated by enhanced immunity, we assess in vivo responses to interferon-lambda by single cell RNA sequencing and measure SARS-CoV-2-specific T cell and antibody responses between placebo and interferon-lambda-treated patients. Here we show that interferon-lambda treatment induces interferon stimulated genes in peripheral immune cells expressing IFNLR1, including plasmacytoid dendritic cells and B cells. Interferon-lambda does not affect SARS-CoV-2-specific antibody levels or the magnitude of virus-specific T cells. However, we identify delayed T cell responses in older adults, suggesting that interferon-lambda can overcome delays in adaptive immunity to accelerate viral clearance in high-risk patients. Altogether, interferon-lambda offers an early COVID-19 treatment option for outpatients to boost innate antiviral defenses without dampening peripheral adaptive immunity.
|
| Notes |
|
Number: 1 Publisher: Nature Publishing Group
|